Sunday 18 October 2026
Export NVAX’s income statement to Excel — free account
Novavax, Inc.
NVAX Healthcare Biotechnology
Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.
11.26
1.56
−12.17%
Follow NVAX
Novavax, Inc. (NVAX) P/E ratio
Novavax, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 4.5× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 2.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 2.5× | (40.03%) |
| Sep 2025 | 4.1× | 69.43% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 4.5×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| NVAX Novavax, Inc. | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| VCEL Vericel Corporation compare | 83.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)